Published 4 days ago • loading... • Updated 4 days ago

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

On January 21, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase 1,600 shares to one newly-hired employee under the 2025 Inducement Plan, the Jan. 30, 2026 release said.
Nektar's 2025 Inducement Plan, adopted November 6, 2025, was approved by Nektar's Board of Directors and is used exclusively for equity awards to newly-hired employees.
An exercise price of $36.92 was set, matching the January 21, 2026 close, with an eight-year term and vesting schedule of 1/4 on one-year anniversary then 1/48 monthly over three years under a stock option agreement.
The Organization and Compensation Committee approved the award under the 2025 Inducement Plan and a stock option agreement, governed by Nasdaq Listing Rule 5635.
Nektar, a clinical-stage biotech, is developing rezpegaldesleukin and noted in its latest release that forward-looking statements are subject to risks, as disclosed in its Form 10-Q filed November 7, 2025.

Insights by Ground AI

16 Articles

The Billings Gazette

+15 Reposted by 15 other sources

Center

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, Jan. 30, 2026 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) today announced that, on January 21, 2026, the Organization and Compensation Committee of Nektar's Board of Directors granted non-qualified stock options to purchase 1,600 shares of its common stock…

4 days ago·Billings, United States

Read Full Article

Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/year